Clinical trial · Observational
CLIMB: CNS Lymphoma Imaging and Molecular Biomarkers Study
A Prospective Imaging and Translational Tissue Study in CNS Lymphoma to Enable Further Disease Characterisation and the Development of Potential Predictive and Prognostic Biomarkers
NCT05828628CI-TRIAL-00090851CLIMBrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A prospective imaging and translational tissue study in CNS lymphoma to enable further disease characterisation and the development of potential predictive and prognostic biomarkers.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| CNS Lymphoma | Central Nervous System Lymphoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Patients with a new diagnosis of primary or secondary CNS lymphoma
Primary outcomes (2)
- measure
- Plasma ctDNA detection
- timeFrame
- 5 Years
- description
- To assess if plasma ctDNA detection measured from end of treatment (using the tumour informed approach) can be used an early detection tool for progressive disease.
- measure
- Contrast clearance analysis
- timeFrame
- 5 Years
- description
- To assess the results of contrast clearance analysis
Secondary outcomes (5)
- measure
- Plasma ctDNA detection from end of treatment
- timeFrame
- 5 Years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Subjects capable of giving informed consent, or if appropriate, if subject's capacity is deemed limited due to CNS involvement, a consultee can provide consent on their behalf. Some patients with PCNSL may be incapable of providing their own consent due to the neurological effects of their disease. In these cases the patient will be classed as an incapacitated adult and a legal representative will be sought in accordance with English or Scottish law as applicable (see 7.2.1) * A radiological or histological diagnosis of primary CNS lymphoma. * Have not received prior CNS directed therapy. Prior use of steroids is permitted. * Participants aged ≥18 years old. Exclusion Criteria: \- Involvement of lymphoma outside of the CNS
References
Publications (0)
Data not yet available
No reference posted for this study.